

ASX / Media Release

Osprey Launches Educational Podcast Series for Investors

July 9, 2019 - Minnesota, United States and Melbourne, Australia – Osprey Medical (ASX: OSP) today announces it has launched a monthly educational podcast series for investors. The podcast series features 5-7 minute discussions with Osprey’s senior management, DyeVert™ customers and other stakeholders, on topics such as acute kidney injury (AKI) reduction and kidney care protocol in US hospitals, relationships with Group Purchasing Organisations (GPOs), sales and marketing of Osprey’s DyeVert system, and other ASX news flow.

The first podcast episode was released on May 16, and introduces investors to DyeVert customer Bobby Kutschman, Director of Cardiology at Methodist Healthcare System. Bobby discusses Metropolitan Methodist Hospital’s successful reduction of AKI incidents by 75 percent by implementing a kidney care protocol including Osprey’s DyeVert system in the cath lab.

The first episode is available at this link: www.ospreymed.com/investor/events-presentations

The second episode released today features a discussion with Osprey Medical VP Clinical Affairs, Kimberly Knish, who speaks about the launch of the Company’s DyeMINISH registry announced in May 2019. Kim talks about the importance of real world data in US healthcare and how the registry will benefit hospitals and healthcare administrators.

The second episode is available at this link: www.ospreymed.com/investor/events-presentations

Osprey Medical CEO Mike McCormick said, “We are delighted to launch an educational series focusing on short stakeholder discussions that provide a deeper insight into how we are meeting the needs of our customers and their patients. The podcast series will also help investors better understand the US healthcare purchasing environment and the growing body of clinical data supporting Osprey’s dye-saving products.”

Osprey Medical will release its Quarterly Appendix 4C Cash Flow Report on Monday, July 15 and its Appendix 4D Half Year Results on Friday, August 16.

– ENDS –

Contact details:

Media

Kyahn Williamson
WE Buchan
M: (61) 401 018 828
kwilliamson@we-buchan.com

Investors

Dr Thomas Duthy
Investor Relations
M: (61) 402 493 727
tduthy@ospreymed.com

Company

Doug Schoenberg
VP of Marketing
T: (952) 955 8230
dschoenberg@ospreymed.com

About Osprey Medical (ASX: OSP)

Osprey Medical's vision is to make heart imaging procedures safer for patients with poor kidney function. The amount of dye (contrast) used during angiographic imaging procedures increases the patient's risk for dye-related kidney damage known as Contrast-Induced Acute Kidney Injury (CI-AKI). The Company's core technologies originated from research conducted by Dr David Kaye at Melbourne's Baker Institute. Its proprietary dye reduction and monitoring technologies are designed to help physicians minimize dye usage and monitor the dose of dye real time throughout the procedure. The Company's DyeVert™ System reduces contrast while maintaining image quality in a self-adjusting easy-to-use design that monitors dye usage. Osprey Medical's Board and Management are comprised of experienced and successful personnel with established track records covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical's advisory board comprises world-recognised experts in heart and kidney diseases.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Osprey does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Osprey may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Foreign Ownership Restriction

Osprey's CHES Depository Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of Osprey's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.